Last 47 quarters of trend data · Healthcare · Drug Manufacturers - General
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 23.17 | 28.05 | 28.09 | 24.72 | 21.19 | 16.64 | 9.01 | 25.72 | 36.35 | 18.93 | 29.51 | 23.46 | 3.81 | 21.11 | — | 33.20 | 24.31 | 24.93 | 23.08 | 24.16 | 29.28 |
| — | +68.6% | +211.6% | -3.9% | -41.7% | -12.1% | -69.5% | +9.6% | +853.2% | -10.3% | — | -29.3% | -84.3% | -15.3% | — | +37.4% | -17.0% | +38.7% | +31.5% | -60.1% | +7.0% | |
| P/S Ratio | 6.53 | 6.14 | 6.11 | 5.15 | 4.55 | 3.88 | 4.53 | 3.91 | 4.36 | 3.94 | 4.49 | 4.45 | 4.65 | 5.05 | 4.83 | 4.96 | 5.44 | 4.98 | 5.07 | 4.60 | 4.60 |
| — | +58.1% | +34.8% | +31.9% | +4.3% | -1.5% | +0.8% | -12.2% | -6.2% | -21.9% | -7.0% | -10.3% | -14.5% | +1.3% | -4.7% | +7.8% | +18.2% | +3.0% | +4.0% | -1.5% | -0.3% | |
| P/B Ratio | 7.61 | 7.31 | 7.24 | 6.21 | 5.51 | 4.70 | 5.08 | 4.92 | 5.59 | 4.95 | 5.49 | 5.54 | 5.58 | 5.69 | 5.70 | 6.13 | 5.83 | 6.27 | 6.36 | 6.17 | 6.11 |
| — | +55.7% | +42.6% | +26.1% | -1.4% | -5.1% | -7.5% | -11.1% | +0.2% | -13.0% | -3.7% | -9.6% | -4.3% | -9.3% | -10.4% | -0.7% | -4.6% | -3.3% | -3.8% | -7.0% | +1.3% | |
| P/FCF | 31.23 | 45.83 | 100.33 | 23.14 | 13.02 | 37.17 | 29.36 | 18.19 | 17.14 | 19.00 | 33.72 | 15.18 | 15.22 | 35.53 | 42.17 | 31.26 | 20.38 | 25.38 | 35.23 | 26.45 | 14.23 |
| — | +23.3% | +241.8% | +27.2% | -24.1% | +95.6% | -12.9% | +19.8% | +12.6% | -46.5% | -20.0% | -51.4% | -25.3% | +40.0% | +19.7% | +18.2% | +43.3% | +1.2% | +10.0% | +76.8% | +11.9% | |
| EV / EBITDA | 19.44 | 22.65 | 18.49 | 17.58 | 13.07 | 11.45 | 12.72 | 15.89 | 14.30 | 10.98 | 12.13 | 15.06 | 12.69 | 13.84 | 13.46 | 21.90 | 15.49 | 15.23 | 15.78 | 18.84 | 12.83 |
| — | +97.8% | +45.4% | +10.7% | -8.6% | +4.3% | +4.8% | +5.5% | +12.8% | -20.7% | -9.9% | -31.3% | -18.1% | -9.1% | -14.7% | +16.3% | +20.7% | +6.1% | +21.0% | +4.3% | -2.3% | |
| EV / EBIT | 25.14 | 22.65 | 24.80 | 25.80 | 15.44 | 14.74 | 7.42 | 22.65 | 28.86 | 15.40 | 25.37 | 19.51 | 18.83 | 17.59 | — | 28.40 | 21.80 | 21.29 | 21.20 | 24.31 | 28.79 |
| — | +53.7% | +234.3% | +13.9% | -46.5% | -4.3% | -70.8% | +16.1% | +53.3% | -12.5% | — | -31.3% | -13.6% | -17.4% | — | +16.8% | -24.3% | +21.3% | +39.3% | -61.8% | +25.6% |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 72.8% | 73.1% | 71.5% | 67.6% | 69.6% | 67.9% | 66.4% | 68.3% | 69.0% | 69.4% | 69.6% | 68.2% | 69.1% | 70.0% | 68.0% | 67.2% | 69.1% | 67.0% | 67.6% | 67.9% | 68.9% |
| — | +7.7% | +7.7% | -1.1% | +0.8% | -2.2% | -4.5% | +0.2% | -0.1% | -0.8% | +2.3% | +1.5% | -0.1% | +4.4% | +0.6% | -1.0% | +0.3% | -0.6% | -1.2% | +4.1% | +3.0% | |
| Operating Margin | 27.2% | 28.3% | 26.6% | 22.8% | 29.6% | 28.7% | 28.8% | 17.1% | 23.5% | 29.7% | 29.3% | 21.5% | 29.0% | 29.5% | 29.9% | 16.5% | 28.3% | 26.9% | 26.1% | 18.0% | 29.4% |
| — | -1.2% | -7.6% | +33.4% | +25.9% | -3.3% | -1.9% | -20.8% | -19.1% | +0.4% | -1.9% | +30.7% | +2.5% | +9.7% | +14.5% | -8.7% | -3.7% | -1.2% | -14.9% | -2.8% | +4.4% | |
| Net Margin | 28.5% | 21.9% | 21.8% | 20.8% | 21.5% | 23.3% | 50.2% | 15.2% | 12.0% | 20.9% | 15.2% | 18.9% | 121.9% | 23.9% | -0.3% | 14.8% | 22.3% | 20.0% | 22.0% | 19.1% | 15.7% |
| — | -6.2% | -56.7% | +36.7% | +79.1% | +11.7% | +230.0% | -19.5% | -90.2% | -12.7% | +4776.6% | +27.5% | +446.8% | +19.3% | -101.5% | -22.2% | +41.9% | -25.6% | -20.8% | +146.9% | -6.8% |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 35.0% | 6.7% | 6.4% | 6.4% | 6.5% | 7.1% | 14.7% | 4.8% | 3.8% | 6.6% | 4.7% | 5.8% | 35.3% | 7.0% | -0.1% | 4.6% | 5.9% | 6.4% | 6.9% | 6.6% | 5.2% |
| — | -5.8% | -56.2% | +31.3% | +71.8% | +6.8% | +213.5% | -16.2% | -89.2% | -5.2% | +5192.7% | +24.4% | +497.0% | +9.6% | -101.3% | -29.2% | +12.6% | -31.3% | -27.9% | +141.3% | -6.0% | |
| ROA | 14.1% | 2.8% | 2.6% | 2.6% | 2.7% | 2.9% | 5.9% | 1.9% | 1.5% | 2.7% | 1.9% | 2.4% | 14.6% | 2.7% | -0.0% | 1.9% | 2.5% | 2.7% | 2.9% | 2.6% | 2.1% |
| — | -3.8% | -55.5% | +36.3% | +77.9% | +7.8% | +206.9% | -21.1% | -89.7% | +0.0% | +5501.1% | +25.0% | +475.8% | -1.8% | -101.2% | -25.9% | +22.5% | -24.8% | -19.9% | +160.7% | -4.5% | |
| ROIC | 19.8% | 4.7% | 4.3% | 3.9% | 4.9% | 5.0% | 5.4% | 3.4% | 4.5% | 6.0% | 6.1% | 4.4% | 5.1% | 4.6% | 4.5% | 2.9% | 4.4% | 5.0% | 4.8% | 3.7% | 5.9% |
| — | -6.4% | -20.4% | +14.2% | +7.6% | -16.0% | -11.8% | -22.6% | -10.8% | +29.3% | +35.4% | +48.8% | +16.0% | -6.6% | -6.5% | -21.1% | -25.2% | -8.6% | -19.7% | +0.1% | +9.1% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.59 | 0.58 | 0.68 | 0.59 | 0.58 | 0.65 | 0.67 | 0.51 | 0.51 | 0.58 | 0.48 | 0.43 | 0.42 | 0.60 | 0.75 | 0.52 | 0.43 | 0.43 | 0.44 | 0.46 | 0.48 |
| — | -10.8% | +1.2% | +14.7% | +13.4% | +11.5% | +39.3% | +20.1% | +21.3% | -2.8% | -35.7% | -17.4% | -2.2% | +39.8% | +68.3% | +13.2% | -11.1% | -11.3% | -13.1% | -18.2% | -17.6% | |
| Debt / EBITDA | 1.45 | 6.84 | 6.55 | 6.31 | 5.16 | 5.80 | 6.47 | 6.39 | 5.02 | 4.92 | 4.16 | 4.55 | 3.73 | 5.50 | 6.51 | 6.98 | 4.36 | 3.97 | 4.20 | 5.34 | 3.91 |
| — | +17.9% | +1.1% | -1.3% | +2.8% | +18.0% | +55.7% | +40.4% | +34.6% | -10.6% | -36.1% | -34.9% | -14.5% | +38.6% | +54.9% | +30.7% | +11.5% | -2.9% | +9.3% | -7.4% | -19.7% | |
| Current Ratio | 1.03 | 1.09 | 1.03 | 1.03 | 1.07 | 1.01 | 1.26 | 1.11 | 1.03 | 1.07 | 1.17 | 1.16 | 1.21 | 1.12 | 1.07 | 0.99 | 1.43 | 1.42 | 1.39 | 1.35 | 1.34 |
| — | +8.3% | -18.5% | -7.5% | +4.4% | -6.2% | +7.5% | -3.9% | -15.0% | -4.1% | +9.7% | +16.6% | -15.5% | -21.5% | -23.4% | -26.5% | +6.6% | +2.6% | +8.5% | +11.8% | -9.3% | |
| Quick Ratio | 0.77 | 0.81 | 0.77 | 0.77 | 0.80 | 0.76 | 1.03 | 0.86 | 0.79 | 0.85 | 0.94 | 0.91 | 0.96 | 0.88 | 0.85 | 0.81 | 1.18 | 1.17 | 1.14 | 1.12 | 1.11 |
| — | +7.2% | -25.4% | -11.3% | +1.3% | -10.4% | +10.5% | -5.6% | -18.0% | -3.8% | +9.6% | +13.3% | -18.5% | -24.7% | -25.0% | -27.9% | +5.9% | +3.7% | +9.5% | +13.5% | -10.1% | |
| Interest Coverage | 34.55 | 115.71 | 23.02 | 24.21 | 30.66 | 22.07 | 67.82 | 29.37 | 18.30 | 22.29 | 24.96 | 32.96 | 28.17 | 30.06 | -5.07 | 24.73 | 102.41 | 154.68 | 587.20 | 81.60 | 193.45 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 47 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
Bull/bear thesis, analyst target revisions, and earnings execution.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying JNJ stock.
Johnson & Johnson's current P/E is 23.2x. The average P/E over the last 4 quarters is 25.5x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Johnson & Johnson's current operating margin is 27.2%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Johnson & Johnson's business trajectory between earnings reports.